The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Vikhrova N.B.

Burdenko Neurosurgical Center

Kalaeva D.B.

Burdenko Center of Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

Postnov A.A.

Burdenko National Medical Scientific Center for Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute);
Lebedev Physical Institute of the Russian Academy of Sciences

Khokhlova E.V.

Burdenko National Medical Scientific Center for Neurosurgery

Konakova T.A.

Burdenko National Medical Scientific Center for Neurosurgery

Batalov A.I.

Burdenko Neurosurgical Center

Pogosbekyan E.L.

Burdenko Neurosurgical Center

Pronin I.N.

Burdenko Neurosurgical Center

Dynamic11C-methionine PET/CT in differential diagnosis of brain gliomas

Authors:

Vikhrova N.B., Kalaeva D.B., Postnov A.A., Khokhlova E.V., Konakova T.A., Batalov A.I., Pogosbekyan E.L., Pronin I.N.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2021;85(3): 5‑13

DOI: 10.17116/neiro2021850315

Views: 4353

Downloaded: 197

Download PDF (RU)
Download PDF
Contact the author
Table of contents

DYNAMIC11C-METHIONINE PET/CT IN DIFFERENTIAL DIAGNOSIS OF BRAIN GLIOMAS
DYNAMIC11C-METHIONINE PET/CT IN DIFFERENTIAL DIAGNOSIS OF BRAIN GLIOMAS

To cite this article:

Vikhrova NB, Kalaeva DB, Postnov AA, et al. . Dynamic11C-methionine PET/CT in differential diagnosis of brain gliomas. Burdenko's Journal of Neurosurgery. 2021;85(3):5‑13. (In Russ., In Engl.)
https://doi.org/10.17116/neiro2021850315

Подписка 2025-2 (Burdenko's Journal of Neurosurgery)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Info­rmation support for the bioresource collection: a biological info­rmation system «NeuroOnc». Burdenko's Journal of Neurosurgery. 2024;(3):65-73
PET/CT with 11C-methionine as a predictor of disease-free survival in patients with IDH1 wild type diffuse glioma. Burdenko's Journal of Neurosurgery. 2024;(5):6-13
Choice of fractionation regi­men for Grade IV gliomas depe­nding on rapid early progression. Burdenko's Journal of Neurosurgery. 2024;(5):23-29
Human glioma mali­gnancy grade and migratory capa­city depe­nding on expression of GDNF isoforms in vitro. Burdenko's Journal of Neurosurgery. 2024;(6):31-38
A Novel Rat Glioblastoma 101/8 Model: A Comparative PET-CT Study with C6 Rat model. Burdenko's Journal of Neurosurgery. 2024;(6):54-62
Magnetic reso­nance imaging and PET/CT with 11C-methionine for primary central nervous system vasculitis. Burdenko's Journal of Neurosurgery. 2024;(6):71-76
Patients with long-term survival in mali­gnant gliomas after photodynamic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):54-61
Own expe­rience in treating patients with progression of anaplastic astrocytomas of the brain. Factors influencing survival. P.A. Herzen Journal of Onco­logy. 2024;(4):35-41
Early chemotherapy between surgery and radiotherapy in grade 4 gliomas. P.A. Herzen Journal of Onco­logy. 2024;(5):12-17
Diagnostic value of cross-sectional imaging moda­lities in asse­ssment of peri­toneal carcinomatosis. P.A. Herzen Journal of Onco­logy. 2024;(5):82-88

OBJECTIVE

To evaluate the possibilities of dynamic preoperative 11C-methionine (MET) PET/CT in differential diagnosis of various types of brain gliomas in adults.

MATERIAL AND METHODS

The study included 74 patients aged 48±14 years with supratentorial gliomas: Grade IV — glioblastoma (GB, n=33), Grade III — anaplastic oligodendroglioma (AOD, n=10) and anaplastic astrocytoma (AA, n=12), Grade II — diffuse astrocytoma (DA, n=13) and oligodendroglioma (OD, n=6). All patients underwent standard MRI and dynamic MET PET/CT within 20 minutes after intravenous injection of radiopharmaceutical. Then, we compared MRI and PET/CT data and comprehensively analyzed the early stages of time-activity curve using 2 parameters: the first pass peak (FPP) and the first peak of maximum uptake (Pmax).

RESULTS

We have significantly distinguished high-grade tumors (GB and AA+AOD) and certain benign gliomas (DA and OD) (p<0.05). AUC was over 0.7 and 0.8 for FPP and Pmax in differential diagnosis of various gliomas, respectively. We found that difficulties in differential diagnosis of gliomas arise mainly if oligodendrogliomas are included in the control group.

CONCLUSION

Dynamic PET/CT with analysis of FPP and Pmax increases specificity of differential diagnosis of various gliomas compared to standard static imaging. These data are valuable for choice of optimal treatment strategy, as well as fundamental research of metabolic processes and vascularization of various tumors.

Keywords:

PET/CT
dynamic PET
11C-methionine
MET
glioma
brain tumor
glioblastoma
anaplastic astrocytoma
oligodendroglioma

Authors:

Vikhrova N.B.

Burdenko Neurosurgical Center

Kalaeva D.B.

Burdenko Center of Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

Postnov A.A.

Burdenko National Medical Scientific Center for Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute);
Lebedev Physical Institute of the Russian Academy of Sciences

Khokhlova E.V.

Burdenko National Medical Scientific Center for Neurosurgery

Konakova T.A.

Burdenko National Medical Scientific Center for Neurosurgery

Batalov A.I.

Burdenko Neurosurgical Center

Pogosbekyan E.L.

Burdenko Neurosurgical Center

Pronin I.N.

Burdenko Neurosurgical Center

Received:

08.06.2020

Accepted:

19.03.2021

List of references:

  1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro-Oncology. 2019;21(Suppl 5):1-100.  https://doi.org/10.1093/neuonc/noz150
  2. Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. The Lancet. Oncology. 2017;18(6):315-329.  https://doi.org/10.1016/S1470-2045(17)30194-8
  3. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, la Fougère C, Langen KJ, Lopci E, Lowe V, McConathy J, Quick HH, Sattler B, Schuster DM, Tonn JC, Weller M. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging. 2018;46(3):540-557.  https://doi.org/10.1007/s00259-018-4207-9
  4. Skvortsova TYu, Zakhs DV, Gurchin AF. PET using [11C]methionine for assessment of cerebral gliomas. Vestnik RONTs im. N.N. Blokhina RAMN. 2016;27(4):61-69. (In Russ.).
  5. He Q, Zhang L, Zhang B, Shi X, Yi C, Zhang X. Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma. BMC Cancer. 2019;19(1):332.  https://doi.org/10.1186/s12885-019-5560-1
  6. Jung J, Ahn B. Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. Brain Tumor Research and Treatment. 2018;6(2): 47-53.  https://doi.org/10.14791/btrt.2018.6.e13
  7. Takei H, Shinoda J, Ikuta S, Maruyama T, Muragaki Y, Kawasaki T, Ikegame Y, Okada M, Ito T, Asano Y, Yokoyama K, Nakayama N, Yano H, Iwama T. Usefulness of positron emission tomography for differentiating gliomas according to the 2016 World Health Organization classification of tumors of the central nervous system. Journal of Neurosurgery. 2019;1-10.  https://doi.org/10.3171/2019.5.JNS19780
  8. Kato T, Shinoda J, Oka N, Miwa K, Nakayama N, Yano H, Maruyama T, Muragaki Y, Iwama T. Analysis of11C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative Activity. American Journal of Neuroradiology. 2008;29(10):1867-1871. https://doi.org/10.3174/ajnr.A1242
  9. Laukamp KR, Lindemann F, Weckesser M, Hesselmann V, Ligges S, Wölfer J, Jeibmann A, Zinnhardt B, Viel T, Schäfers M, Paulus W, Stummer W, Schober O, Jacobs AH. Multimodal Imaging of Patients With Gliomas Confirms 11C-MET PET as a Complementary Marker to MRI for Noninvasive Tumor Grading and Intraindividual Follow-Up After Therapy. Molecular Imaging. 2017;16:153601211668765. https://doi.org/10.1177/1536012116687651
  10. Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y, Shinoda J, Yano H, Iwama T. Evaluation of brain tumors using dynamic 11C-methionine-PET. Journal of Neuro-Oncology. 2012;109(1):115-122.  https://doi.org/10.1007/s11060-012-0873-9
  11. Moulin-Romsée G, D’Hondt E, de Groot T, Goffin J, Sciot R, Mortelmans L, Menten J, Bormans G, Van Laere K. Non-invasive grading of brain tumours using dynamic amino acid PET imaging: does it work for 11C-Methionine? European Journal of Nuclear Medicine and Molecular Imaging. 2007;34(12):2082-2087. https://doi.org/10.1007/s00259-007-0557-4
  12. Nomura Y, Asano Y, Shinoda J, Yano H, Ikegame Y, Kawasaki T, Nakayama N, Maruyama T, Muragaki Y, Iwama T. Characteristics of time-activity curves obtained from dynamic 11C-methionine PET in common primary brain tumors. Journal of Neuro-Oncology. 2018;138(3):649-658.  https://doi.org/10.1007/s11060-018-2834-4
  13. Batalov AI, Zakharova NE, Pogosbekyan EL, Fadeeva LM, Goryaynov SA, Baev AA, Shults EI, Chelushkin DM, Potapov AA, Pronin IN. Non-contrast ASL perfusion in preoperative diagnosis of supratentorial gliomas. Voprosy neirokhirurgii imeni N.N. Burdenko. 2018;82(6):15-22. (In Russ.). https://doi.org/10.17116/neiro20188206115
  14. Tyurina AN, Pronin IN, Fadeeva LM, Batalov AI, Zakharova NE, Podoprigora AE, Shults EI, Kornienko VN. Proton 3D MR spectroscopy in the diagnosis of glial brain tumors. Meditsinskaya vizualizatsiya. 2019;3:8-18. (In Russ.). https://doi.org/10.24835/1607-0763-2019-3-8-18
  15. Zhukov VYu, Goryaynov SA, Buklina SB, Vologdina YaO, Batalov AI, Ogurtsova AA, Kulikov AS, Kobyakov GL, Sitnikov AR, Chernyshov KA, Chelushkin DM, Zakharova NE, Potapov AA. Intraoperative mapping of long association fibers in surgery of gliomas of the speech-dominant frontal lobe. Zhurnal voprosy neirokhirurgii imeni N.N. Burdenko. 2018;82(5): 5-21. (In Russ.). https://doi.org/10.17116/neiro2018820515
  16. Falk Delgado A, Falk Delgado A. Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: a bivariate diagnostic test accuracy meta-analysis. The British Journal of Radiology. 2018; 91(1082):20170426. https://doi.org/10.1259/bjr.20170426
  17. Takahashi M, Soma T, Mukasa A, Tanaka S, Yanagisawa S, Momose T. Pattern of FDG and MET Distribution in High- and Low-Grade Gliomas on PET Images. Clinical Nuclear Medicine. 2019;44(4):265-271.  https://doi.org/10.1097/rlu.0000000000002460
  18. Katsanos A, Alexiou G, Fotopoulos A, Jabbour P, Kyritsis A, Sioka C. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading. Clinical Nuclear Medicine. 2019;44(11):864-869.  https://doi.org/10.1097/rlu.0000000000002654
  19. Okubo S, Zhen H, Kawai N, Nishiyama Y, Haba R, Tamiya T. Correlation of l-methyl-11C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas. Journal of Neuro-Oncology. 2010;99(2):217-225.  https://doi.org/10.1007/s11060-010-0117-9
  20. Nawashiro H, Otani N, Uozumi Y, Ooigawa H, Toyooka T, Suzuki T, Katoh H, Tsuzuki N, Ohnuki A, Shima K, Shinomiya N, Matsuo H, Kanai Y. High expression of L-type amino acid transporter 1 in infiltrating glioma cells. Brain Tumor Pathology. 2005;22(2):89-91.  https://doi.org/10.1007/s10014-005-0188-z

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.